leadf
logo-loader
viewGenprex, Inc.

Genprex develops 'Acclaim' branding for upcoming combination lung cancer trials of its drug REQORSA

The trials will pair Genprex's drug with AstraZeneca’s Tagrissoib and separately with Merck’s Keytruda

Lung xray or some other medical result
The idea is to encourage early exposure of Genprex’s clinical programs to patients, healthcare practitioners, clinical investigators, investors, employees and others

Genprex Inc (NASDAQ:GNPX) has launched new branding for the upcoming oncology clinical trials combining its lead drug candidate REQORSA with AstraZeneca’s Tagrissoib and separately with Merck’s Keytruda for the treatment of non-small cell lung cancer (NSCLC).

These trials will use the brand name, “Acclaim,” which the company believes evokes the enthusiasm and hope these trials represent for NSCLC patients and the oncology community. Acclaim-1 will refer to the Tagrisso combination clinical trial, and Acclaim-2 will refer to the Keytruda combination clinical trial.

The idea is to encourage early exposure of Genprex’s clinical programs to patients, healthcare practitioners, clinical investigators, investors, employees and others. The company plans to initiate both Acclaim clinical trials in the first-half of 2021. 

READ: Genprex promotes Eric Chapdelaine to VP of manufacturing

“We are enthusiastically preparing for our upcoming clinical trials and are excited to launch the adoption of this branding,” CEO Rodney Varner said in a statement. “We believe the Acclaim brand communicates our passion for providing hope to NSCLC patients for important new treatment options in the fight against this devastating disease and aligns us with the clinical, medical and patient communities.”

Acclaim-1 is a Phase 1/2 clinical trial using a combination of REQORSA with Tagrisso in patients with late-stage NSCLC with mutated epidermal growth factor receptors (EGFRs) whose disease progressed after treatment with Tagrisso. Acclaim-2 is a Phase 1/2 clinical trial using a combination of REQORSA with Keytruda in NSCLC patients who are low expressors (1 to 49%) of the protein, programmed death-ligand 1 (PD-L1).

Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Genprex, Inc.

Price: 3.09 USD

NASDAQ:GNPX
Market: NASDAQ
Market Cap: $122.42 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Genprex launches new branding for its lead drug REQORSA in preparation for...

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive the Texas-based group has launched new branding for the upcoming oncology clinical trials combining its lead drug candidate REQORSA with AstraZeneca’s Tagrissoib and separately with Merck’s Keytruda for the treatment of non-small cell...

3 weeks, 2 days ago

2 min read